Carbapenem-resistant Enterobacteriaceae Testing Market

Carbapenem-resistant Enterobacteriaceae Testing Market Outlook (2024 to 2034)

The global carbapenem-resistant enterobacteriaceae testing market is estimated at a value of US$ 4.25 billion in 2024 and is forecasted to reach a size of US$ 8.89 billion by 2034-end. Worldwide demand is projected to advance at a 7.7% CAGR from 2024 to 2034.

One key factor driving the market growth is the increasing incidences of infections brought on by enterobacteriaceae that are resistant to carbapenem. Serious health problems resulting from CRE infections make accurate diagnosis and treatment of these cases imperative. To facilitate timely treatment and infection control measures, CRE needs to be identified quickly in clinical settings. Quick diagnostic tests shorten the time it takes to get findings, which enhances patient outcomes and slows the spread of infections in medical institutions. Diagnostic technology advancements, such as next-generation sequencing and PCR are improving the sensitivity and specificity of CRE testing. These developments are facilitating the utilization of effective testing procedures at laboratories, which is further driving the market expansion.

North America is analyzed to account for 37.7% of global market share in 2024. The high prevalence of antibiotic-resistant illnesses and strong healthcare infrastructure in this region, especially the United States are making it a lucrative market. The Western Europe region is estimated to generate a turnover of US$ 925.51 million in the current year (2024). Demand for carbapenem-resistant enterobacteriaceae testing is increasing in Western European countries, including the United Kingdom, Germany, and France due to the rising number of multidrug-resistant infection cases.

By test type, modified hodge carbapenem-resistant enterobacteriaceae testing is holding a 49.5% portion of the overall revenue in 2024 and is further forecasted to increase to 50.5% by the end of 2034. Demand for this test is high due to its reliability, simplicity, and cost-effectiveness. As a phenotypic test, the MHT is widely used in clinical laboratories to identify carbapenemase-producing organisms, which are responsible for the resistance observed in CRE infections.

Report Attributes	Details
Carbapenem-resistant Enterobacteriaceae Testing Market Size (2024E)	US$ 4.25 Billion
Forecasted Market Value (2034F)	US$ 8.89 Billion
Global Market Growth Rate (2024 to 2034)	7.7% CAGR
North America Market Share (2024E)	37.7%
Western Europe Market Value (2024E)	US$ 925.51 Million
South Asia & Pacific Market Growth Rate (2024 to 2034)	9.6% CAGR
Modified Hodge Segment Value (2034F)	US$ 4.49 Billion
Hospitals Segment Value (2034F)	US$ 4.41 Billion
Key Companies Profiled	TBA; SolGent Co., Ltd.; ELITechGroup; ALIFAX S.r.l.; bioMérieux, Inc.; Cepheid; Siemens Healthineers; Roche Diagnostics; Thermo Fisher Scientific; Abbott Laboratories; Merck Group; Hoffmann-La Roche

Enterobacteriaceae are a family of germs that most commonly live in a person’s bowel without causing any disease. Carbapenems are strong antibiotics that are commonly used to treat serious infections. A few enterobacteriaceaea have gained resistance to these antibiotics. These are called Carbapenem-resistant Enterobacteriaceae. Carbapenem-resistant Enterobacteriaceae testing is considered to be a gram-negative pathogen testing. Common gram-negative pathogens include Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumonia, Enterobacter aerogenes, and Acinetobacterbaumannii.

These gram-negative pathogens are mediated and treated by transferable carbapenemase-encoding genes. A few infections caused by carbapenem-resistant Enterobacteriaceae outside the bowel include wound infection, urinary tract infection (UTI), and pneumonia. People prone to Carbapenem-resistant enterobacteriaceae include people admitted to hospitals or other healthcare settings. According to The Centers for Disease Control and Prevention (CDC), around 2 million people are infected by antibiotic-resistant organisms every year, which further leads to approximately 23,000 deaths annually.

The mortality rates are also high, ranging from 40%-50%. Two major factors responsible for this kind of infection are the use of mechanical ventilation and the use of beta-lactam antibiotics. Beta-lactam antibiotics include Cephalosporins, Penicillins, monobactams, and Carbapenems. Carbapenem-resistant enterobacteriaceae testing includes disc diffusion or automated systems, selective agar Carbapenem-resistant enterobacteriaceae testing, minimal inhibitory concentration (MIC) for Carbapenem-resistant enterobacteriaceae testing, synergy Carbapenem-resistant enterobacteriaceae testing, modified Hodge tests, whole genome sequencing, spectrometrics, and various other molecular methods.

Carbapenem-resistant Enterobacteriaceae Testing Market: Drivers

People admitted to any healthcare setting for medical care are more prone to infection and go for Carbapenem-resistant enterobacteriaceae testing than healthy people. Increase in the number of people requiring inpatient medical assistance, a growing number of healthcare facilities, an increased number of complex surgeries, multiple uses of several antibiotics, and a rise in the use of medical devices in the body, such as urinary catheters, intravenous catheters, and ventilators, are few of the major factors responsible for growth in the Carbapenem-resistant enterobacteriaceae testing market.

Growing awareness about the prevention of Carbapenem resistance and increased efforts by governments through the implementation of infection prevention and control measures might hinder the growth of the Carbapenem-resistant enterobacteriaceae testing market during the forecast period.

Carbapenem-resistant Enterobacteriaceae Testing Market: Overview

In Carbapenem-resistant Enterobacteriaceae Testing, Modified Hodge tests are anticipated to be one of the leading test types for Carbapenem-resistant enterobacteriaceae testing because of the high accuracy of test results. These tests are easy to perform and easily performed in a routine laboratory, which makes them more feasible and thus, one of the leading test types in the carbapenem-resistant enterobacteriaceae testing market.

Molecular testing detects the resistance mechanism whereas phenotypic tests detect the in-vitro activity of carbapenemase enzyme. Healthcare settings, such as nursing homes and acute care centers, where constant medical care is required for a longer duration of time are more prone to CRE and thus, the demand for Carbapenem-resistant enterobacteriaceae testing is higher in these settings.

Carbapenem-resistant Enterobacteriaceae Testing Market: Regional Outlook

According to The Centers for Disease Control and Prevention (CDC), by 2013 Carbapenem-resistant enterobacteriaceae was found in almost 42 states. CDC also stated that the enterobacteriaceae proportion of Carbapenem-resistance has consistently increased and has increased four-fold in the past ten years. During the early 2000s, CRE was rare in the North American region.

However, the breakout of CRE in the northeast spread through the US, thereby boosting the market for Carbapenem-resistant enterobacteriaceae testing in the region. The Asia Pacific market for Carbapenem-resistant enterobacteriaceae testing is also expected to expand during the forecast period because of the detection of different classes of carbapenemase.

Carbapenem-resistant Enterobacteriaceae Testing Market: Key Players

Some of major participants operating in the Carbapenem-resistant Enterobacteriaceae Testing market are

• TBA
• SolGent Co., Ltd.
• ELITechGroup
• ALIFAX S.r.l.
• bioMérieux, Inc.
• Cepheid
• Siemens Healthineers
• Roche Diagnostics
• Thermo Fisher Scientific
• Abbott Laboratories
• Merck Group
• Hoffmann-La Roche

The report is a compilation of first-hand information, qualitative and quantitative assessments by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

The report covers an exhaustive analysis on

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Regional analysis includes

• North America
  • US
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Peru
  • Rest of LATAM
• Europe
  • EU – 4 (Germany, France, Italy, Spain)
  • UK
  • BENELUX (Belgium, Netherlands, Luxemburg)
  • NORDIC (Norway, Denmark, Iceland, Sweden)
  • Eastern Europe (Poland, Ukraine, Czech Rep. Etc.)
  • Rest of Europe
• CIS & Russia
• Japan
• APEJ
  • Greater China
  • India
  • Korea
  • ASEAN Countries
  • Rest of APEJ
• Middle East & Africa
  • GCC Countries
  • Turkey
  • Iran
  • Israel
  • South Africa
  • Rest of MEA

Report Highlights

• Detailed overview of parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint.

Segmentation of Carbapenem-resistant Enterobacteriaceae Testing Market Research

• By Test Type :

  • Modified Hodge
  • Minimal Inhibitory Concentration
  • Others

• By End User :

  • Hospitals
  • Ambulatory Surgical Centers
  • Intensive Care Units
  • Clinics
  • Nursing Homes
  • Long-Term Acute Care Centers

• By Region :

  • North America
  • Western Europe
  • Eastern Europe
  • Latin America
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa